Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Ebola vaccine approved as a second tested sample

Ebola vaccine approved as a second tested sample

  Man receives Ebola vaccine in DR Congo Copyright

Caption image

A man is given the Ebola vaccine in DR Congo

A second Ebola vaccine is to be offered to about 50,000 people in the Democratic Republic of the Congo, as part of a major clinical trial.

The vaccine for Johnson and Johnson (J&J) will be used in conjunction with a vaccine made by Merck, which has already been provided to about 250,000 people.

Merck's Strike has already been approved by the World Health Organization.

More than 2,1

00 people have died in the DRC, the second-largest ebola outbreak currently.

The WHO endorsement of the single-dose Merck vaccine is based on the satisfaction of its safety and efficacy. The European Commission has also approved the vaccine.

The J&J vaccine, which requires two doses distributed over 56 days, will be available to adults and children over one living in two areas of DR Congo, Goma, where there is no active transmission of the deadly disease.

Goma, which has a population of one million people, is on the border with Rwanda and has a large international airport.

Prof. Daniel Bausch, director of the UK's rapid public health support team, is one of the leading scholars in the lawsuit.

He said that there was no "race" between the two vaccines, and both had their advantages and disadvantages.

The measure given to those who come into direct and indirect contact with an Ebola patient can be best used in the middle of an outbreak – while the J&J vaccine can be used to protect people who are still are not exposed to Ebola.

Johnson & Johnson

Prof. Bausch said, "The J&J vaccine is not ideally suited to establishing an epidemic, primarily because it requires two doses to provide optimal immunity."

But he said the vaccine "can provide longer-term immunity and can be associated with fewer side effects from a live viral vaccine, such as Merck's. "

The number of new cases of the DRC Ebola epidemic has dropped significantly from its height in the spring, but there are still about 20 new infections reported each week.

Dr. Jeremy Farrar, director of the Wellcome Trust, which helps fund the J&J trial, was a "critical step forward".

"Previous studies have shown that the J&J vaccine produces an immune response, which is a good indicator that it will be protected against the Ebola virus."


Dr. Eteni Longongo, Minister of Public Health in the DRC, said: "It is vital that we step up our efforts. That is why we are working with international partners to provide our response teams with another fighting tool and ultimately stop the spread of this terrible disease. "

The outbreak is fueled by misinformation and hearing, along with an extremely difficult security situation.

About 200 health facilities have been attacked since the outbreak in August 2018, so the introduction of a new vaccine in already skeptical communities is

Immunization teams from the medical charity Médecins Sans Frontières (MSF) will administer the vaccine. to bring It is to misconceptions, which means that community involvement will be crucial before and during deployment of the second investigative vaccine. "

Source link